Page last updated: 2024-11-12

azd8309

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

AZD8309: CXCR2 inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12073810
CHEMBL ID446458
SCHEMBL ID841899
MeSH IDM0574772

Synonyms (16)

Synonym
CHEMBL446458 ,
bdbm50371784
SCHEMBL841899
SRHSMXLXWORYJK-SSDOTTSWSA-N
5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1r)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2-(3h)-one
azd8309
8PD78CVU5V
thiazolo[4,5-d]pyrimidin-2(3h)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1r)-2-hydroxy-1-methylethyl]amino]-
azd-8309
5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1r)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3h)-one
(r)-5-((2,3-difluorobenzyl)thio)-7-((1-hydroxypropan-2-yl)amino)thiazolo[4,5-d]pyrimidin-2(3h)-one
333742-48-6
HY-119259
CS-0077438
5-[(2,3-difluorophenyl)methylsulfanyl]-7-[[(2r)-1-hydroxypropan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one
AKOS040746606

Research Excerpts

Treatment

Treatment with AZD8309 showed a mean 77% reduction in total sputum cells (p < 0.001) and 79% Reduction in neutrophils (p = 0.05) compared with placebo after LPS challenge.

ExcerptReferenceRelevance
"Treatment with AZD8309 showed a mean 77% reduction in total sputum cells (p < 0.001) and 79% reduction in sputum neutrophils (p < 0.05) compared with placebo after LPS challenge. "( Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
Barnes, PJ; Leaker, BR; O'Connor, B, 2013
)
0.74
"Treatment with AZD8309 reduced the leucocyte count to 48% of placebo 6 h after the LPS challenge."( Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor.
Cardell, LO; Ekman, AK; Jansson, L; Virtala, R; Westin, U, 2012
)
0.72

Bioavailability

ExcerptReferenceRelevance
" We have investigated the effect of AZD8309, a potent and orally bioavailable antagonist of the chemokine receptor CXCR2, which has been proposed to regulate the transmigration of neutrophils."( Effect of oral administration of AZD8309, a CXCR2 antagonist, on the severity of experimental pancreatitis.
D'Haese, J; Günther, A; Hansen, MB; Kärrman Mårdh, C; Lerch, MM; Mahajan, UM; Malla, SR; Mayerle, J; Sendler, M; Weiss, FU,
)
0.69

Dosage Studied

AZD8309 (300 mg) or placebo was dosed twice daily orally for 3 days prior to challenge with inhaled LPS. induced sputum was collected 6 h later.

ExcerptRelevanceReference
" AZD8309 or placebo was dosed for 3 days."( Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor.
Cardell, LO; Ekman, AK; Jansson, L; Virtala, R; Westin, U, 2012
)
1.29
" AZD8309 (300 mg) or placebo was dosed twice daily orally for 3 days prior to challenge with inhaled LPS and induced sputum was collected 6 h later."( Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
Barnes, PJ; Leaker, BR; O'Connor, B, 2013
)
1.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-X-C chemokine receptor type 2Homo sapiens (human)IC50 (µMol)0.00100.00000.30296.0130AID1193191; AID316041
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-X-C chemokine receptor type 2Homo sapiens (human)Kd0.00130.00130.00130.0013AID1193196
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 2Homo sapiens (human)pA20.00600.00600.00600.0060AID316047
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (62)

Processvia Protein(s)Taxonomy
dendritic cell chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-X-C chemokine receptor type 2Homo sapiens (human)
signal transductionC-X-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cell population proliferationC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil chemotaxisC-X-C chemokine receptor type 2Homo sapiens (human)
receptor internalizationC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
neutrophil activationC-X-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-X-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 2Homo sapiens (human)
immune responseC-X-C chemokine receptor type 2Homo sapiens (human)
cytokine-mediated signaling pathwayC-C chemokine receptor type 2Homo sapiens (human)
blood vessel remodelingC-C chemokine receptor type 2Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
monocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
regulation of T cell cytokine productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T-helper 1 type immune responseC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of type 2 immune responseC-C chemokine receptor type 2Homo sapiens (human)
intracellular calcium ion homeostasisC-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
humoral immune responseC-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of adenylate cyclase activityC-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATC-C chemokine receptor type 2Homo sapiens (human)
response to woundingC-C chemokine receptor type 2Homo sapiens (human)
regulation of vascular endothelial growth factor productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of angiogenesisC-C chemokine receptor type 2Homo sapiens (human)
sensory perception of painC-C chemokine receptor type 2Homo sapiens (human)
cellular homeostasisC-C chemokine receptor type 2Homo sapiens (human)
hemopoiesisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of type II interferon productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of interleukin-2 productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionC-C chemokine receptor type 2Homo sapiens (human)
monocyte extravasationC-C chemokine receptor type 2Homo sapiens (human)
T-helper 17 cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of eosinophil degranulationC-C chemokine receptor type 2Homo sapiens (human)
regulation of T cell differentiationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of alpha-beta T cell proliferationC-C chemokine receptor type 2Homo sapiens (human)
homeostasis of number of cells within a tissueC-C chemokine receptor type 2Homo sapiens (human)
regulation of inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T cell activationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicC-C chemokine receptor type 2Homo sapiens (human)
leukocyte adhesion to vascular endothelial cellC-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of monocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of immune complex clearance by monocytes and macrophagesC-C chemokine receptor type 2Homo sapiens (human)
inflammatory response to woundingC-C chemokine receptor type 2Homo sapiens (human)
neutrophil clearanceC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cold-induced thermogenesisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of leukocyte tethering or rollingC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of NMDA glutamate receptor activityC-C chemokine receptor type 2Homo sapiens (human)
macrophage migrationC-C chemokine receptor type 2Homo sapiens (human)
regulation of macrophage migrationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of thymocyte migrationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of monocyte extravasationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of CD8-positive, alpha-beta T cell extravasationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of astrocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of hematopoietic stem cell migrationC-C chemokine receptor type 2Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
immune responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
interleukin-8 receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
interleukin-8 bindingC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 2Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-C chemokine receptor type 2Homo sapiens (human)
CCR2 chemokine receptor bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 2 bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 12 bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 7 bindingC-C chemokine receptor type 2Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleoplasmC-X-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
cell surfaceC-X-C chemokine receptor type 2Homo sapiens (human)
microtubule cytoskeletonC-X-C chemokine receptor type 2Homo sapiens (human)
membraneC-X-C chemokine receptor type 2Homo sapiens (human)
secretory granule membraneC-X-C chemokine receptor type 2Homo sapiens (human)
mast cell granuleC-X-C chemokine receptor type 2Homo sapiens (human)
mitotic spindleC-X-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 2Homo sapiens (human)
fibrillar centerC-C chemokine receptor type 2Homo sapiens (human)
cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
cytosolC-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-C chemokine receptor type 2Homo sapiens (human)
membraneC-C chemokine receptor type 2Homo sapiens (human)
dendriteC-C chemokine receptor type 2Homo sapiens (human)
neuronal cell bodyC-C chemokine receptor type 2Homo sapiens (human)
perikaryonC-C chemokine receptor type 2Homo sapiens (human)
perinuclear region of cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID316046Distribution coefficient, log D of the compound2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Evaluation of a series of bicyclic CXCR2 antagonists.
AID1193201Clearance in iv dosed rat2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID1193196Antagonist activity at CXCR2 receptor in HEK293 cells assessed as mobilization of intracellular calcium by FLIPR analysis2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID1193194Fraction unbound in human plasma by equilibrium dialysis method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID1193204Dose normalized AUC in po dosed rat2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID316042Oral bioavailability in rat2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Evaluation of a series of bicyclic CXCR2 antagonists.
AID1193195Lipophilicity, log D of the compound by shake flask technique2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID1193193Dissociation constant, pKa of the compound2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID316043Clearance in rat2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Evaluation of a series of bicyclic CXCR2 antagonists.
AID1193197Intrinsic clearance in human hepatocytes assessed per 10'6 cells2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID316044Protein binding as % unbound in human plasma2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Evaluation of a series of bicyclic CXCR2 antagonists.
AID316047Antagonist activity at human CCR2 in THP1 cells by FLIPR2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Evaluation of a series of bicyclic CXCR2 antagonists.
AID316041Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Evaluation of a series of bicyclic CXCR2 antagonists.
AID1193192Solubility of the compound in 0.1 M phosphate buffer at pH 7.4 after overnight incubation by HPLC analysis2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID1193191Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID1193202Volume of distribution at steady state in iv dosed rat2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID316045Dissociation constant, pKa of the compound2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Evaluation of a series of bicyclic CXCR2 antagonists.
AID1193200Fraction of the dose absorbed in iv dosed rat2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID1193199Bioavailability in iv dosed rat2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
AID1193203Half life in iv dosed rat2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (40.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]